NasdaqGS:BMRNBiotechs
BioMarin Pharmaceutical (BMRN): Evaluating Valuation Following Strong Q2 Results and Barclays’ Reaffirmed Buy Rating
BioMarin Pharmaceutical (BMRN) has been stirring up investor conversation lately after delivering its fiscal Q2 2025 results, which highlighted solid revenue growth and a jump in earnings per share compared to last year. The company also received a vote of confidence as Barclays reaffirmed its Buy outlook right after the report, calling attention to BioMarin’s promising pipeline, particularly advancing therapies such as Valoctocogene roxaparvovec, Vosoritide, and BMN 307. With these updates,...